Abstract Mathematical models have been used to simulate HIV transmission and to study the use of preexposure prophylaxis (PrEP) for HIV prevention. Often a single intervention outcome over 10 years has been used to evaluate the effectiveness of PrEP interventions. However, different metrics express a wide variation over time and often disagree in their forecast on the success of the intervention. We develop a deterministic mathematical model of HIV transmission and use it to evaluate the public-health impact of oral PrEP interventions. We study PrEP effectiveness with respect to different evaluation methods and analyze its dynamics over time. We compare four traditional indicators, based on cumulative number or fractions of infections prevented, on reduction in HIV prevalence or incidence and propose two additional methods, which estimate the burden of the epidemic to the public-health system. We investigate the short and long term behavior of these indicators and the effects of key parameters on the expected benefits from PrEP use. Our findings suggest that publichealth officials considering adopting PrEP in HIV prevention programs can make better informed decisions by employing a set of complementing quantitative metrics.
Introduction
In 2010, evidence from two different randomized clinical trial suggested that preexposure prophylaxis (PrEP) products based on antiretroviral drug Tenofovir taken orally as a pill (oral PrEP) or applied topically in the form of gel (vaginal microbicides) can help prevent HIV. First, the CAPRISA 004 trial demonstrated a 39 % (95 %CI, 6 % to 60 %) overall decrease in HIV incidence among women in the VMB arm of the trial who were advised to use the product before and after each sex act (Karim et al. 2010) . Later, the Global iPrEx trial of a daily use of a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) demonstrated a 43.8 % efficacy (95 %CI, 15 % to 63 %) to reduce HIV acquisition among men-who-have sex with men (MSM) (Grant et al. 2010) . Although these products await confirmation from another trial to move toward licensure or label change, there is already a broad discussion on what will be population-level benefits from wide-scale PrEP use in high prevalence settings.
Mathematical models have been used to simulate HIV transmission and to study the use of chemoprophylaxis among MSM (Desai et al. 2008; Supervie et al. 2010) . Deterministic mathematical models of HIV heterosexual transmission stratified by gender have been analyzed in Dimitrov et al. (2010 Dimitrov et al. ( , 2011 , Abbas et al. (2007) , Vissers et al. (2008) , Pretorius et al. (2010) , Wilson et al. (2008) . Often a single intervention outcome based on cumulative number or fractions of infections prevented, on reduction in HIV prevalence or incidence has been used to evaluate the effectiveness of PrEP interventions. These indicators express a wide variation over time and often disagree in their forecast on the success of the intervention (Dimitrov et al. 2010; Wilson et al. 2008) . Therefore, the conclusions of many modeling studies are significantly influenced by the choice of the evaluation method and the period of evaluation. In particular, it has been pointed out that indicators based on prevented infections tend to show mixed results over time due to their sensitivity to changes in population dynamics (Dimitrov et al. 2011) .
In this paper, we develop a deterministic mathematical model of HIV transmission to evaluate the public-health impact of oral PrEP interventions, compare PrEP effectiveness with respect to different evaluation methods, and analyze its dynamics over time. We compare four traditional evaluation methods including relative reduction in HIV prevalence and incidence, which avoid the ambiguity associated with commonly used indicators based on the absolute number of prevented infections. We consider two additional methods, which estimate the burden of the epidemic to the public-health system. We then investigate the short term and long term behavior of these indicators and the effects of key parameters on the expected benefits from PrEP use. The effects of demographic, behavioral, and epidemic parameters on the PrEP impact are studied in a multivariate sensitivity analysis.
Model Description and Analysis
In our models (see Fig. 1 ), the population is divided into two major classes, PrEP users (superscript p, S p + I p ) and those that do not use PrEP (S + I ), and further stratified according to their HIV status into susceptible (S, S p ) and infected (I , I p ). Individuals who develop AIDS are accumulated in nonsexually active class A. Individuals join the community (reaching sexual maturity) and departure from the sexually active population at constant rates (Λ, μ) . A proportion k of the new recruits start using PrEP. PrEP users are assumed to strictly follow the prescribed regimens. The model which assumes that PrEP reduces both susceptibility and infectiousness of the users ("dual-protection" model) is formulated by the following system of differential equations:
Since the differential equations for these four compartments are independent from the AIDS class (A), we do not include it in our ODE system. Here, N = S p + S + I p + I represents the sexually active population and α s (α i ) measures the efficacy of PrEP in reducing susceptibility (infectiousness) of PrEP users. The cumulative HIV acquisition risk per year β is calculated based on the HIV risk per act (b a ) with a HIV-positive partner and the average number of sex acts per year (n):
Cumulative acquisition risk (β) is an increasing function with respect to HIVacquisition risk per act b a and average number of sexual acts per year n.
PrEP is introduced at time (t = 0) in a population with N(0) = 1,000,000 and HIV-prevalence (P ). We assume that PrEP is initially adopted by a fraction k 1 of the individuals and that the initial fraction of HIV-positive individuals is reduced by θ as a result of preenrollment HIV screening: The initial distribution of the epidemic classes may not be critical for the asymptotic behavior of the system, but it is essential for the impact indicators calculated over fixed periods of time after the start of the intervention. To isolate the impact of the choice of the evaluation method, we simplify the intervention schedule and assume instantaneous uptake of PrEP at a predetermined level (k = k 1 ).
Clinical trials in HIV prevention are usually designed to evaluate the efficacy of the tested products in reducing susceptibility (α s ) only. Although a reduction in infectiousness (α i ) is plausible, it is not verifiable since all HIV positive participants are immediately withdrawn from the product. Moreover, the biomedical products currently in testing are based on antiretroviral drugs, and are not recommended for use by infected individuals due to the risk of drug resistance development. Therefore, the majority of the modelers assume unidirectional PrEP protection (α i = 0), which means that using PrEP has no effect on the infectiousness or that infected individuals do not take PrEP anymore. This scenario may also represent the idea of control of the PrEP usage by the HIV-positive individuals since fast removal of the infected users from PrEP is the equivalent of setting α i = 0. To address that possibility, we consider a "single-protection" model in which the variable I p is removed from the baseline model as follows:
with initial conditions:
In our analysis, HIV epidemics are simulated in presence and in absence of PrEP. If PrEP is not available, the "no intervention" model is reduced to the following system:
with S(0) = (1 − P )N(0) and I (0) = P N(0).
Modeling Assumptions
Several important assumptions are incorporated into the model:
• The HIV prevalence in the whole population is representative for the HIV prevalence among each gender, i.e., the chance to have a HIV-positive partner is proportional to the total HIV prevalence.
• Individuals are assumed to have a fixed number of sex acts per year.
• Sexual behavior of an individual does not change if he/she starts using PrEP but sexual activity stops once AIDS is developed.
• The use of PrEP reduces both HIV susceptibility and infectiousness and by this reduces the HIV acquisition risk per sex act.
• We assume perfect adherence to PrEP: individuals who start using PrEP continue to follow the prescribed regimen indefinitely. However, the scenario with no reduction of infectiousness due to PrEP (α i = 0) is equivalent to immediate withdrawal from PrEP after HIV acquisition.
• The use of other HIV prevention measures including condom use, male circumcision, and ARV treatments are not considered separately in our model. Their effects on HIV transmission are aggregated in the HIV acquisition risk per act.
Equilibrium Analysis
The "no intervention" model (3), has two steady states: infection free equilibrium ( Λ μ , 0) and endemic equilibrium (
They exchange stability when the basic reproduction number R 0 = β μ+d crosses the threshold of one. In epidemiology, the basic reproduction number (sometimes called basic reproductive rate or basic reproductive ratio) of an infection is the mean number of secondary infections a typical single infected individual will cause in a population with no immunity to the disease in the absence of interventions to control the infection. It is often denoted by R 0 . This metric is useful because it helps determine whether or not an infectious disease will spread through a population. In general, if R 0 > 1, then the infection free steady state is unstable and the infection persists in the population while if R 0 < 1 then the infection free steady state is stable and the infection may be eradicated. That is exactly the case for the HIV epidemic modeled by the "no intervention" model (3). A simple application of the Dulac criterion ensures that model (3) does not generate nontrivial periodic solution.
The "single-protection" model (2) has an infection free steady state (
However, the positive steady states for these two models, when they exist, are too complicated to be expressed explicitly.
Model Parametrization
We used demographic and HIV prevalence data representative for the sexually active population (15-49 years old) in South Africa for the period between 2001 and 2011 provided by the Statistical Institute of South Africa (Mid-year population estimates 2011) to parameterize our models in the scenario without PrEP.
First, we estimate the recruitment rate in the sexually active population (Λ). We base our calculations on the approximated number of 15-year olds ( population aged 15 to 19 5 = 5175400 5 = 1035100) and the total population size (27,172,400) aged 15 to 49, in year 2011. In our model without PrEP, we assume initial total sexually active population to be N = 10 6 . Therefore, we scale the estimated entrance rate to obtain the recruitment of the sexually active population (Λ) in our model: Λ = 10 6 · 1035100 27172400 ≈ 38094, which we use in the epidemic simulations. Next, we fit the projected HIV prevalence ) comparison of the epidemic dynamics projected by the "dual-protection," "single-protection," and "no intervention" models using baseline parameter values from Table 1 and the best-fitting estimates obtained by the "no intervention" model for the period 2001-2011 ( Fig. 2(a) ) as well as its long-term projections ( Fig. 2(b) ).
Epidemic Projections
We present the epidemic dynamics obtained by the "dual-protection" model (1) using the baseline parameter values from Table 1 in Fig. 3 (a) and compare them with the projections of the "single-protection" (2) and "no intervention" (3) models in Fig. 3(b) .
We observe that all simulations approach steady states after a period of 200 years. A 50 % efficacious PrEP, which reduces both susceptibility and infectiousness of its users will stabilize on disease-free equilibrium if PrEP is used consistently by 20 % 
(T )
Incidence indicator Reduction in the annual HIV incidence at time t = T due to the usage of PrEP
Reduction in the projected number of infections at time t = T due to the usage of PrEP
Fractional reduction indicator Fraction of the projected number of infections at time t = T reduced due to the usage of PrEP of the all sexually active individuals. A unidirectional PrEP protection, simulated by the "single-protection" model, will not be enough to eliminate HIV from the South African population but will reduce the infected population significantly. However, it is not straightforward to evaluate the population level impact of PrEP from the longterm epidemic projections. Therefore, it is very important to find biologically reasonable metrics to quantify the effectiveness of PrEP interventions. We introduce several indicators and study their behavior under different scenarios over various time periods. We also compare the indicators readings for different interventions to understand how the choice of metric and/or duration affects the relative public-health impact of PrEP projected with mathematical models.
Effectiveness Indicators
The impact of PrEP in our analysis is evaluated by the quantitative indicators described in Table 2 . The first four indicators are widely used in modeling studies to evaluate the impact of interventions over fixed periods [0, T ] . The cumulative and the fractional indicators measure the intervention effectiveness based on the infections prevented in scenarios with PrEP compared to scenarios without PrEP. The prevalence and incidence indicators measure the reduction of the projected HIV prevalence and incidence due to PrEP. We propose the last two evaluation methods based on the reduction of the number of infected individuals as they are closely related to the economic burden of the HIV epidemic on the public health system at community and state level since the money allocated for HIV treatment is proportional to the size of the infected population.
Predictions of mathematical models based on quantitative indicators are often used to estimate the effectiveness of novel interventions and to compare the expected benefits from different prevention options. The analytical conclusions in favor of specific option are usually based on evaluations of the indicators over a few fixed periods of intervention time, most likely 10 years but almost certainly between 5 and 30 years. Table 1 However, all indicators vary over time and may express different preferences when used to decide between comparable prevention programs. We illustrate the idea with a comparison of the indicator dynamics for two hypothetical PrEP interventions. Intervention 1 assumes no control of the PrEP use by HIV-positive individuals (θ = 0) and 50 % PrEP efficacy in reducing both susceptibility and infectiousness (α s = α i = 0.5) while Intervention 2 requires a negative HIV test as a condition for prescribing PrEP (θ = 1) and better PrEP efficacy in reducing infectiousness (α s = 0.5, α i = 0.9). Each of the incidence, prevalence, and fractional indicators shows increasing effectiveness of both interventions over 50 years after initiation of PrEP (Fig. 4 ) with more benefits attributed to Intervention 1 initially, but higher impact of Intervention 2 in a longterm. However, they disagree on the timing when the advantage of the Intervention 1 ends. For instance, a preference to Intervention 2 is given after 17 years of PrEP use if based on reduction in HIV incidence and after 22 years if based on reduction in HIV prevalence. The public-health impact of Intervention 1 measured in terms of cumulative fraction of prevented infections remains higher compared to Intervention 2 for up to 32 years which is substantially longer than the evaluation periods used in the majority of the quantitative analyses. Therefore, if PrEP is evaluated over periods between 17 and 32 years the choice of quantitative indicator is critical. We take a closer look at the key drivers of those discrepancies in the indicators' dynamics.
Indicator Expressions
To utilize the calculation of the cumulative indicators, we need to keep track of the cumulative number of new infections. For this reason, we add two equations to the "dual-protection" model (1):
and add an equation to the "single-protection" model (2): If PrEP is not available, the "no intervention" model becomes:
with initial conditions S(0)
We proceed with analysis of the behavior of the indicators assuming "dual protection." For the remainder of the paper, we use [ ] to denote variables from the model without PrEP (6) and [ ] DP for variables from the "dual-protection" model with PrEP (4). Using these notations, the qualitative indicators have the following expressions:
(T )+I (T ) S p (T )+S(T )+I p (T )+I (T ) ] DP [ I (T ) S(T )+I (T ) ]
Since integral evaluated on derivative function can be simplified, previous expressions of the indicators are equivalent to the following:
] ,
From these expressions, we can see that the indicators F I , P I , aI I , andF I are dimensionless and attain value in [0, 1], and they do not depend on the population size. The other two indicators C I andĈ I measure changes in population group sizes, and are not dimensionless.
Initial Dynamics of the Indicators
To understand the practical value of the qualitative indicators, we examine their short, intermediate, and long term dynamics. We begin with indicator approximations shortly after the start of the intervention. Using the initial conditions defined above, we obtained the following expressions associated with the initial indicators' behavior (details can be found in the Appendix):
Here, we assume dt = 1 for the approximation for aI I because the definition of the incidence indicator is on annual basis.
Note that the expression for the fractional indicator (F I ) depends only on the PrEP efficacy (α s , α i ) and factors related to the implementation of the intervention at its start such as initial coverage (k 1 ) and the introductory control of the PrEP usage by HIV-positive individuals (θ ) but not on the demographic, behavioral, and epidemic parameters. Therefore, fractional indicator represents a metric of the "immediate impact of PrEP" on the HIV epidemic, which is independent of the specific population and the status of the HIV epidemic in it. This metric accounts for the effects of the reduced susceptibility (α s ) of the fraction k 1 of the population which initially uses PrEP combined with the reduced infectiousness (α i ) of a limited fraction (1 − θ)k 1 of the infected population when in contact with partners unprotected by PrEP (1 − α s k 1 ). Clearly, if PrEP provides unidirectional protection (α i = 0) or none of the infected individuals is using PrEP (θ = 1), then the "immediate impact of PrEP" is given by the product of PrEP efficacy and coverage (α s k 1 ). The initial behavior of all other indicators depend on the HIV prevalence (P ) at the time of PrEP introduction as well as on the cumulative HIV-acquisition risk (β). Moreover, the cumulative (C I ) and reduction (Ĉ I ) indicators also depend on the initial population size (N(0)), which is consistent with the fact that only indicators C I andĈ I measure changes on population group sizes, and are not dimensionless.
The initial rate of change of the indicators can be approximated as:
Notice that initially C I ≈Ĉ I and P I ≈F I . We study the sensitivity of the initial rate of change of the reduction indicators (Ĉ I andF I ) to some of the intervention (θ , k 1 ) and epidemic (P ) parameters by bifurcation simulations (Fig. 5) . These bifurcation parameters were chosen because they are easier to evaluate at community levels compared to HIV-acquisition risk and PrEP efficacy. The graphs in Fig. 5(a) and (b) demonstrate that the growth of both indicators accelerates if more people start on PrEP (larger k 1 ), but decelerates if the control of the PrEP usage by infected individuals is more effective (larger θ ). The initial rate of change is more sensitive to k 1 than to θ but it is clear that the growth rate of both indicators at the time of PrEP introduction expresses qualitatively similar behavior with respect to the intervention parameters (θ , k 1 ). In contrast, the graphs presenting the dependence on the initial HIV prevalence show serious discrepancies (Fig. 5(c) ). The initial growth rate of the reduction indicator (Ĉ I ) increases when the HIV prevalence ranges from 0 to 50 % which includes all realistic values observed so far, particularly in Sub-Saharan Africa (Fig. 5(c) ). In comparison, the increase in HIV prevalence within the same range implies smaller growth rate of the fractional reduction indicatorF I .
Asymptotic Behavior of the Indicators
In resource-constrained settings, it is unrealistic to expect the HIV epidemic will die out without additional intervention. Therefore, in the following, we assume that the basic reproduction number of the "no intervention" model is R 0 > 1. The asymptotic HIV prevalence in this case is given by:
We want to point our that if the PrEP intervention is strong enough to cause the eradication of HIV in the population, i.e., the HIV epidemic approaches the diseasefree equilibrium with the "dual-protection" model, then the asymptotic behavior of all indicators is well determined: (i) the cumulative indicator will grow to infinity; (ii) the reduction indicator will stabilize at [I ] = R 0 −1 β−d Λ; and (iii) all other indicators will approach one. Unfortunately, PrEP intervention alone is unlikely to be sufficient to eradicate HIV. In that case, we show that the asymptotic behavior of the indicators can be expressed in terms of the asymptotic proportion (p) of the HIV-positive subpopulation, which have been infected while using PrEP (details are presented in the Appendix), where p is defined as follows:
Expressions for the asymptotic values of four of the indicators:
and the asymptotic rate of growth of the cumulative indicator:
show that they are independent of the initial HIV prevalence (P ) and the control on the PrEP use by HIV-positive individuals (θ ), which have been of critical importance for the initial dynamics of the indicators. Cumulative indicators (Ĉ I and C I ) depend indirectly on the population size (N ), which determines the entry rate in the population (Λ). Notice that C I = (μ + d)Ĉ I so the value of the reduction indicator is proportional to the annual number of new infections prevented due to PrEP use in a long term. The rest of the indicators are not influenced by the population size (N ).
Although recruitment parameters such as k and Λ are not explicitly present in some of the expressions above they may affect the asymptotic proportion of PrEP users among infected subpopulation (p). Therefore, a good approximation of p is important for the evaluation of the asymptotic levels of the indicators. Boundedness of the prevalence indicator P I < 1 and Table 1 positivity of the annual incidence indicator both imply that
This provides a rough approximation for p. We study the variation of p when the reduction in susceptibility and infectiousness range from 0 to 100 % ( Fig. 6(a) ) for intervention coverage (k = 0.1) which is not sufficient to eradicate HIV even if the PrEP protection against HIV is perfect (α s = α i = 1). It shows that p depends greatly on the reduction in susceptibility (α s ) and very little on the reduction in infectiousness (α i ). It is clear that the fraction of infections, which occur when using PrEP (p) ranges from zero, in case that PrEP provides complete protection against HIV (α s = 1) and no PrEP users ever get infected, to the level of the PrEP coverage (k) in case that PrEP is completely ineffective (α s = 0) and infections are proportionally distributed among PrEP users and nonusers. Our next goal is to examine and compare the long-term behavior of the indicators (specifically those expressed as ratios) for a fixed PrEP intervention (Fig. 6(b) ). Although qualitatively similar, the trajectories of the indicators show some important differences. First, some indicators such as the reduction in HIV prevalence and the reduction in the infected fraction start at zero while others such as the fraction of prevented infections and the reduction in HIV incidence initiate at positive values. Therefore, it is not surprising that the indicators reach a specific threshold of 20 % at times varying from 3 to 11 years after the introduction of PrEP. The times needed to report 50 % effectiveness are even farther apart. It takes the intervention 24 years and 33 years to reduce in half the expected HIV incidence and HIV prevalence, respectively. However, almost 90 years are necessary to reduce the cumulative number of new infections by 50 %, i.e., such reduction is infeasible over traditionally used evaluation periods of up to 30 years. Table 1 effectiveness is evaluated. The same period is recommended by the World Health Organizations as an evaluation period when cost-effectiveness analyses are conducted (World Health Organization (WHO) 2003). Longer periods are investigated in few studies but always up to 30 years.
In this section, we explore the dependence of the indicator readings over 10 and 30 years on key epidemic and intervention parameters. Clearly, the impact of PrEP is positively correlated with both reductions in susceptibility (α s ) and infectiousness (α i ) regardless of what indicator is used to quantify it (Fig. 7) . The slopes of the contour plots in the PrEP efficacy parameter space show that if the susceptibility efficacy(α s ) is relatively low (up to 30 %), all indicators are equally dependent of both α s and α i . However, with the increase of the PrEP protection against HIV, the influence of the reduction of infectiousness decreases significantly. The prevalence indicator (P I ) projects the least effectiveness over 10 years of PrEP use. It predicts that more than 70 % and 55 % PrEP efficacy is needed to achieve 20 % reduction in HIV prevalence with uni-directional (α i = 0) and bidirectional (α i = α s ) interventions, respectively. In comparison, 20 % reduction in the expected HIV infections is possible with 65 % effective unidirectional and 55 % bidirectional PrEP while 20 % reduction in HIV incidence is feasible even if less than 45 % effective unidirectional and 30 % bidirectional PrEP is used over 10 years. The order of predicted effectiveness by the prevalence and the fractional indicators is reversed over an evaluation period of 30 years. More than half of the parameter space results in more than 50 % reduction in HIV prevalence (P I ), an unreachable threshold as a reduction in expected infections (F I ).
All indicators increase with coverage k = k 1 (Fig. 8) . The prevalence and fractional indicators, in contrast to the incidence indicator, are sensitive to changes in the transmission rate (β) with increasing influence of β on the fraction of prevented infection for larger evaluation periods. The maximum PrEP effectiveness over 10 years of PrEP use is predicted for complete coverage (k) and modest level of the transmission rate (β) while over 30 years it is achieved for the lowest possible β.
Sensitivity Analysis
Finally, we explore the sensitivity of the indicators to changes in each parameter. Using the algorithm presented in Blower and Dowlatabadi (1994) , we calculate the Partial Rank Correlation Coefficients (PRCC), which evaluate the monotonicity of the model outcomes (indicators) in terms of the model parameters. Values of PRCC closer to ±1, imply stronger correlation between the output indicator and the input parameter while the sign of the coefficients determines if the outcomes grow or decrease with an increase of the input parameters.
We study separately the sensitivity of the indicators to the parameters (b a , n, μ, and d) which we fitted using data from South Africa. In our analysis, we choose 1,000 random parameters combinations of those input parameters sampled uniformly from their corresponding ranges: Table 1 ). The rest of the parameters are fixed on their baseline values in Table 1 . For each parameter set, we simulate the models with "dual-protection" and no intervention and calculate PRCC matrix of all six indicators C I , F I , P I , aI I ,Ĉ I , andF I for the first 10 years (standard analysis) as well as for the 100 years (long-term analysis). Similarly, we investigate the indicators' sensitivity to the remaining epidemic and intervention parameters (α s , α i , P , k 1 (k = k 1 ), and θ ), uniformly sampled from their corresponding ranges: Correlations for 10-year intervention suggest that from the fitted parameters the indicators are most sensitive to the factors (b a and n), which determine the transmission rate β. However, their influence over time decreases. C I andĈ I are still positively correlated to the two factors while the rest of the indicators are negatively correlated to the two factors over 100 years, both dependencies are weak. The intervention outcomes are split into two groups with respect to their correlation with the HIV induced mortality (d): the cumulative indicators being negatively correlated while the rest being positively correlated with d. Similar discrepancy is observed with respect to the influence of the initial HIV prevalence P over 10 years, but the correlations are reversed (positive-for the cumulative indicators and negative for the rest). Interestingly, in that case the difference between the indicators disappears in a long term. Note that although P appears in the initial conditions only, it continues to have strong influence on all the cumulative and reduction indicators for more than 10 years while its impact on the fraction of prevented infection gets even stronger over time.
Among the intervention parameters, PrEP coverage (k) and PrEP efficacies per act (α s and α i ) express strong positive correlation with all the indicators in a short term. It remains significant in a long term for all outcomes. This confirms that PrEP coverage and protection level are critical to the intervention success regardless which qualitative metric is used. In contrast, the influence of the initial control on the PrEP use by HIV-positive individuals (θ ) reduces substantially in time.
The prevalence (P I ) and the annual incidence (aI I ) indicators express almost the same sensitivity to all parameters. Therefore, they should have consistent projections when evaluating the impact of the intervention.
Conclusions
Precise evaluation of the expected public-health impact of biomedical interventions for HIV preventions becomes increasingly important with more prevention options entering the pipeline toward licensure. The practice shows that even if the products are effective in reducing the individual risk of acquisition (individual efficacy) the benefits from general usage (population effectiveness) may be limited by variety of epidemic, behavioral, and intervention factors. In this paper, we analyzed different evaluation metrics of population effectiveness of pre-exposure prophylaxis (PrEP) interventions. We compare four traditional indicators, based on cumulative number or fractions of infections prevented, on reduction in HIV prevalence or incidence with other two metrics based on the reduction in infected subpopulation.
We demonstrated that the quantitative indicators have a distinct dynamical profile shortly after the start of PrEP intervention which modifies substantially over time. As a result, when calculated over a fixed period of time, these indicators may project significantly different PrEP effectiveness and, therefore, influence the decision if particular products are potentially good enough for implementation. In general, new prevention methods need to prove their effectiveness in randomized clinical trial (RCT), i.e., to demonstrate that the observed efficacy is significantly larger than zero (positive 95 % confidence interval), before applying for licensure. In reality, developers and public-health officials try to avoid PrEP products with low efficacy because the controlled environments of the clinical trials are difficult to be replicated at community level. Another concern is that the availability of PrEP may affect sexual behavior and encourage risk-sex practices. Therefore, minimal efficacy thresholds of 20 % or higher are often included in the design of RCTs and similar levels of effectiveness is expected when interventions are modeled at population level (Grant et al. 2010; Partners PrEP Study Team 2011; Dimitrov et al. 2013) . Other studies imply that 50 % biological efficacy is needed to guarantee significant public-health impact. The question remains what does 20 % or 50 % PrEP effectiveness mean? We have shown the widely used evaluation metrics may disagree over practical intervals of time (Fig. 6) . A reduction in HIV incidence at pre-specified levels seems most realistic as an intervention goal, but it is not easy to be estimated in the population. In contrast, a reduction in HIV prevalence is easier to be recorded but more difficult to be achieved in a short term. The reduction in the number of new HIV infections, which is the most popular public-health metric, projects strong PrEP effectiveness initially but grows slower than the other indicators over time.
Moreover, if used to compare the impact of PrEP interventions different indicators may give preference to different options (Fig. 4) . We recommend that public-health officials who consider PrEP to be integrated in HIV prevention programs should base their decision on a complex of quantitative metrics. Although is specifically focused on HIV prevention, the same theoretical approach may be extended to model other infectious diseases, such as malaria, cholera, and tuberculosis (Mtisi et al. 2009; Mwasa and Tchuenche 2011) or evaluate the impact of interventions, such as male circumcision, vaccination, or quarantine strategies (Mubayi et al. 2010; Alsallaq et al. 2010; Hallett et al. 2011; Foss et al. 2003; Blower et al. 2001) . The proposed metrics comparison may be useful when the influence of different behavior factors, such as sexual disinhibition, smoking, or drinking on the epidemics dynamics is studied (Bhunu et al. 2011; Mubayi et al. 2011) .
Presented results, assuming perfect adherence and instantaneous uptake, are likely to give optimistic views of the potential impact of a PrEP intervention. Although, overall self-reported adherence in the concluded clinical trials is high it is unclear how consistently PrEP will be used in real settings. That will depend among other things on the delivery system (e.g., coital or daily use, oral, topical, or slow release ring), individual preferences, availability, acceptability, and cost of the product (Eisingerich et al. 2012; Greene et al. 2010) . Perfect adherence and other simplifying assumptions allowed us to support our observations on the indicators and their simulated dynamics with analytical expressions, which were easier to be interpreted. We believe that more complex and realistic modeling setup will be more useful in projecting benefits due to PrEP use but it is unlikely to resolve the differences between the interventional outcomes reported in this paper.
Author's personal copy
Then by the expression of prevalence indicator, we have
Thus, the slope at which the prevalence indicator increases at the beginning of the intervention can be approximated by
By the expression of cumulative indicator, we have 
A.2 Asymptotic Approximations of the Indicators
To approximate the asymptotic behavior of indicators, we need to study the steady state of the two models. What is challenging is to study the steady state of the baseline model using PrEP (4). For the cumulative indicator at the steady state, we have
We see that the cumulative indicator keeps increasing, and eventually the rate approaches a constant. Finally, we look at the annual incidence indicator 
